241 related articles for article (PubMed ID: 28565796)
1. Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.
Wang J; Lu W; Li J; Zhang R; Zhou Y; Yin Q; Zheng Y; Wang F; Xia Y; Chen K; Li S; Liu T; Lu J; Zhou Y; Guo CY
Exp Ther Med; 2017 May; 13(5):1977-1985. PubMed ID: 28565796
[TBL] [Abstract][Full Text] [Related]
2. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis.
Tandon P; Abraldes JG; Berzigotti A; Garcia-Pagan JC; Bosch J
J Hepatol; 2010 Aug; 53(2):273-82. PubMed ID: 20570385
[TBL] [Abstract][Full Text] [Related]
3. Renin-Angiotensin Aldosterone System Inhibitors and COVID-19: A Systematic Review and Meta-Analysis Revealing Critical Bias Across a Body of Observational Research.
Loader J; Taylor FC; Lampa E; Sundström J
J Am Heart Assoc; 2022 Jun; 11(11):e025289. PubMed ID: 35624081
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
[TBL] [Abstract][Full Text] [Related]
5. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
6. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
Nochioka K; Sakata Y; Shimokawa H
Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis.
Campbell KN; Pennese N; Zaffalon A; Magalhaes B; Faiella M; Caster DJ; Radhakrishnan J; Tesar V; Trachtman H
Kidney Med; 2022 May; 4(5):100457. PubMed ID: 35518835
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
[TBL] [Abstract][Full Text] [Related]
9. β-Blocker withdrawal is preferable for accurate interpretation of the aldosterone-renin ratio in chronically treated hypertension.
Browne GA; Griffin TP; O'Shea PM; Dennedy MC
Clin Endocrinol (Oxf); 2016 Mar; 84(3):325-31. PubMed ID: 26300226
[TBL] [Abstract][Full Text] [Related]
10. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
Weir MR; Rolfe M
Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
[TBL] [Abstract][Full Text] [Related]
11. Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.
Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M
Clin J Am Soc Nephrol; 2020 Aug; 15(8):1129-1138. PubMed ID: 32675281
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dual vs single renin-angiotensin-aldosterone system blockade in chronic kidney disease: An updated meta-analysis of randomized controlled trials.
Zhao M; Qu H; Wang R; Yu Y; Chang M; Ma S; Zhang H; Wang Y; Zhang Y
Medicine (Baltimore); 2021 Sep; 100(35):e26544. PubMed ID: 34477114
[TBL] [Abstract][Full Text] [Related]
13. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
Feng YH; Fu P
Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
[TBL] [Abstract][Full Text] [Related]
14. Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries.
Ouwerkerk W; Teng TK; Tromp J; Tay WT; Cleland JG; van Veldhuisen DJ; Dickstein K; Ng LL; Lang CC; Anker SD; Zannad F; Hung CL; Sawhney JPS; Naik A; Shimizu W; Hagiwara N; Wander GS; Anand I; Richards AM; Voors AA; Lam CSP
Eur J Heart Fail; 2020 Aug; 22(8):1472-1482. PubMed ID: 32583922
[TBL] [Abstract][Full Text] [Related]
15. Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.
Kim JH; Kim JM; Cho YZ; Na JH; Kim HS; Kim HA; Kang HW; Baik SK; Kwon SO; Cha SH; Kim YJ; Kim MY
Clin Mol Hepatol; 2014 Dec; 20(4):376-83. PubMed ID: 25548744
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008117. PubMed ID: 24488616
[TBL] [Abstract][Full Text] [Related]
17. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological interventions for hypertension in children.
Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
[TBL] [Abstract][Full Text] [Related]
19. Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?
Bavishi C; Bangalore S; Messerli FH
Prog Cardiovasc Dis; 2016; 59(3):253-261. PubMed ID: 27777044
[TBL] [Abstract][Full Text] [Related]
20. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
